Acetazolamide Lozenges as the Promising Candidate for Prophylaxis of High Altitude Sickness

The present study aimed to formulate and evaluate Acetazolamide as a lozenge to combat flaws in regard to conventional dosage form. Mountain sickness is a distressing disease common in the estimated hundred million who briskly ascend from lower altitudes to elevations above 2500 m. around the world. It is manifests with headache, which is often associated with fatigue, lightheadedness, anorexia, nausea, vomiting and disturbed sleep with frequent awakening. Acetazolamide is a carbonic anhydrase inhibitor works by shortening the period of high altitude acclimatization by inhibiting conversion of carbon dioxide to bicarbonate, the resultant metabolic acidosis may also increase oxygenation during hypoxia. Lozenges were manufactured by heating and congealing method with sucrose with dextrose as a base of lozenge and HPMC E5 in varying concentrations. Preformulation illustrated compatibility of excipients and drugs coordinated using FT IR. Post formulation parameters were studied. Formulation F2 was considered as excellent medicated confection that met all the requirements showing adequate hardness and disintegration of 10.3 kg cm2 and 9.24 minutes respectively with a strong drug release rate of 99.14 . The acetazolamide lozenges can be a better approach for high altitude problems in prevention as well as treatment in emergency conditions with shorter half life. Bhushan Suryakant Mali | Prashant B. Patil | Rushikesh S. Bachhav "Acetazolamide Lozenges as the Promising Candidate for Prophylaxis of High Altitude Sickness" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-1 , December 2021, URL: https://www.ijtsrd.com/papers/ijtsrd49085.pdf Paper URL: https://www.ijtsrd.com/medicine/other/49085/acetazolamide-lozenges-as-the-promising-candidate-for-prophylaxis-of-high-altitude-sickness/bhushan-suryakant-mali